Topic: Mrna Flu

Dr. Peter Hotez is criticized for his shifting stance on vaccine technologies, specifically his recent comments regarding whole inactivated virus vaccines. Hotez argued that older vaccine technologies are prone to side effects like Guillain-Barre syndrome, citing the 1976 swine flu incident. The hosts suggest that the medical establishment is now disparaging traditional vaccines to protect the market dominance of mRNA technology.

The BBC reports on the development of mRNA vaccines for Norovirus, traditionally known as the "24-hour bug." The hosts discuss the symptoms of the virus, including intense gastrointestinal distress, and note its recent branding as a major public health threat. Vaccination rates for the flu and COVID-19 are reportedly lower than desired, leading to increased media pressure for uptake.

Moderna announced positive trial results for a combined COVID-19 and flu vaccine, aiming for federal approval by 2025. Dr. Ashish Jha appeared on Chris Cuomo's show to promote the shot, dismissing concerns about mRNA by stating it is naturally present in every cell of the body. The hosts criticize the "native ad" style of the reporting and express skepticism about vaccine safety.

The U.S. government is reportedly nearing an agreement to fund Moderna's bird flu vaccine trials, causing the company's stock to rise. The hosts suggest the push for bird flu awareness is a precursor to implementing mail-in voting or new masking mandates. They discuss the transition from traditional egg-based vaccine manufacturing to mRNA "platforms" or "operating systems."

The show concludes with a discussion on the development of a universal flu vaccine using mRNA technology, which aims to protect against all 20 known strains. Global health organizations like the WEF and WHO are promoting the shot as a "transformative product" for everyone on the planet. The segment ends with a satirical musical piece and final sign-offs from the hosts.

Pfizer CEO Albert Bourla discussed the progress of an mRNA-based flu vaccine during an interview at Davos. He indicated that clinical trial data is expected in the first half of 2023, with a potential launch later in the year. Bourla also confirmed that Pfizer is experimenting with a combined COVID-19 and flu vaccine to streamline future immunization efforts.

Scientists have developed an experimental "super vaccine" using mRNA technology designed to fight 20 different strains of the influenza virus. Unlike traditional flu shots that target specific predicted strains, this universal approach aims to provide a baseline level of immunity against all known flu proteins. Florida Governor Ron DeSantis has criticized the continued push for mRNA platforms following the COVID-19 rollout.

Researchers at Johns Hopkins are promoting the transition of flu vaccines to the mRNA platform, which can be manufactured in 100 days without using chicken eggs. This shift is presented as a way to better match circulating strains like H3N3. Additionally, a senior-specific vaccine called Flu Block is being produced using insect cells rather than traditional egg-based methods.

Health officials detected vaccine-derived polio virus type 2 in London sewage samples, the first sign of local spread since 2003. This outbreak is being used to argue for a total transition to mRNA technology to avoid "vaccine-derived" complications. There is further speculation that bird flu outbreaks and the culling of chickens are being used to intentionally disrupt the traditional egg-based vaccine supply chain.

In a Washington Post interview, Pfizer CEO Albert Bourla admits that choosing mRNA technology was "counterintuitive" because the company had more experience with traditional vaccine methods. He reveals that his team "convinced" him to use mRNA despite it never having delivered a commercial product before the COVID-19 vaccine.

Financial journalist Andrew Ross Sorkin questioned Scott Gottlieb regarding the necessity of a second booster for those over 50. Gottlieb predicted that the term "booster" will be replaced by "annual vaccine," mirroring the seasonal flu shot model. Both Pfizer and Moderna are developing Omicron-specific vaccines, with data expected to be released in May 2022.

Health officials are suggesting that COVID-19 boosters may become a regular requirement similar to annual flu shots. The hosts discuss the potential transition of traditional flu vaccines to MRNA technology, noting that over 3 billion MRNA doses have already been administered globally. They speculate on the timeline for the pandemic's end, targeting April or May 2022 as a possible conclusion.

Moderna announced plans for a single-shot mRNA booster that combines vaccines for COVID-19, the flu, and RSV. Meanwhile, the Biden administration is committing $2 billion to purchase 300 million rapid tests for distribution to schools and food banks. The move toward recurring boosters is described as immunity as a service, requiring constant participation to maintain fully vaccinated status.

A 2013 clip of Dr. Anthony Fauci discussing the H3N2 flu season shows him using nearly identical rhetoric to his current COVID-19 messaging regarding vaccine "matching" and protection. The segment explores the long-term goal of developing a universal flu vaccine using mRNA technology, a project that has been in development since the 1990s. This historical context suggests the current pandemic is being used to accelerate a pre-existing pharmaceutical agenda.

Former FDA Commissioner Scott Gottlieb discusses the potential for a severe flu season due to a lack of natural immunity built up during the pandemic. The segment explores the transition toward mRNA technology for future influenza vaccines and how vaccinated individuals should assess their personal risk.

Moderna CEO Stéphane Bancel stated on CNBC that the company expects to sell annual COVID-19 boosters through 2024. Moderna is working to combine flu and COVID-19 vaccines into a single annual shot, arguing that the virus will stabilize similarly to the seasonal flu.